Lung Cancer |

Epidemiological and Survival Analysis of Bronchopulmonary Carcinoids, 2000 - 2010 FREE TO VIEW

Hari Prasad Ravipati, MD; Srinadh Annangi, MBBS; Swathi Nutakki, MBBS; Christine Charaf, MD; Eric Flenaugh, MD
Author and Funding Information

Morehouse School of Medicine, Atlanta, GA

Chest. 2014;145(3_MeetingAbstracts):336A. doi:10.1378/chest.1778840
Text Size: A A A
Published online


SESSION TITLE: Lung Cancer Posters I

SESSION TYPE: Poster Presentations

PRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PM

PURPOSE: Bronchopulmonary (BP) carcinoids are rare neuroendocrine tumors comprising of 1.1 % of all pulmonary cancers. To our knowledge no single study had been done using large cancer database evaluating bronchopulmonary carcinoids in particular with respect to their anatomical distribution and the impact of staging, histological grade, treatment offered and racial distribution on five year relative survival rates.

METHODS: We analyzed the Surveillance, Epidemiology, and End Results (SEER) database from 18 registries for anatomical, demographic and histological distribution of bronchopulmonary carcinoids and their survival impact.

RESULTS: Of the 6225 bronchopulmonary carcinoids, 4235(68%) were diagnosed in females and 1990(32%) in males. 90% cases were whites, 6.9% blacks, 2.3% Asian/Pacific islanders and 0.3% Native American/Alaskan. 5yr relative survival rates were 80.2% in blacks and 90.2% in whites. BP carcinoids account for 20.09% of all carcinoids of which 8.11% were lower lobe (LL), 5.85% upper lobe(UL) and 3.55% middle lobe(ML) tumors. 5yr relative survivals for bronchial, upper lobe, middle and lower lobe carcinoids are 89.0%, 88.9%, 96.0% and 91.2% respectively. Atypical carcinoids comprise of 7% of bronchopulmonary carcinoids with 5yr relative survival rate of 62.8%. 66.1% had localized, 17.6% regional and 11.7% distant spread BP carcinoids and their relative survival rates were 97.9%, 84.2% and 54.1% respectively. 69.9%, 17.6%, 9.4% of UL carcinoids, 74%, 16.3%, 6.6% of ML and 68.4%, 17.8%, 9.4% of LL carcinoids are staged as having localized, regional and distant spread respectively. Survival rates in non-surgical cases were 56.8% compared to 96.8% for surgical cases.

CONCLUSIONS: There has been over all increase in the incidence of bronchopulmonary carcinoids, more common in females with female to male ratio of 2.1:1. Incidence rates were highest in the seventh decade of life. Low survival rates in blacks could be attributed to lower surgery rates in blacks (71.2%) compared to whites (83%). Staging is a strong predictor of survival. Upper lobe carcinoid in males with distant spread had the least survival rate. Surgery definitely increases 5yr relative survival rates.

CLINICAL IMPLICATIONS: Staging is the strongest predictor of survival. Upper lobe carcinoids in males has least survival. Surgery remains the main stay of treatment for BP carcinoids.

DISCLOSURE: The following authors have nothing to disclose: Hari Prasad Ravipati, Srinadh Annangi, Swathi Nutakki, Christine Charaf, Eric Flenaugh

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543